USPTO Examiner ARON KIMBERLY A - Art Unit 1633

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18672959TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USEMay 2024March 2025Allow920NoNo
18672979TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USEMay 2024March 2025Allow920NoNo
18582361COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDFebruary 2024August 2024Allow610NoNo
18682853HIGH-THROUGHPUT PRECISION GENOME EDITING IN HUMAN CELLSFebruary 2024May 2025Abandon1620NoNo
18431504POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOFFebruary 2024September 2024Allow810YesNo
18510460ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPYNovember 2023January 2025Abandon1420NoNo
18371959TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USESeptember 2023July 2024Allow1020YesNo
18447651COMPOSITIONS AND METHODS COMPRISING ENGINEERED SHORT NUCLEAR RNA (SNRNA)August 2023February 2024Allow700NoNo
18322961ONCOLYTIC VIRUSES FOR MODIFIED MHC EXPRESSIONMay 2023December 2023Allow710NoNo
18105374Oncolytic Immunotherapy by Tumor Micro-Environment RemodelingFebruary 2023May 2025Allow2740NoNo
18080253ONCOLYTIC VIRUSES FOR MODIFIED MHC EXPRESSIONDecember 2022February 2024Allow1410NoNo
18079749AAV-Mediated Gene Transfer for RetinopathyDecember 2022September 2024Abandon2120YesNo
18052801GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING HYDROXYACID OXIDASE 1 (HAO1) AND USES THEREOFNovember 2022September 2023Allow1110YesNo
17964465GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUSOctober 2022June 2023Allow810YesNo
17846868ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPYJune 2022August 2023Allow1310YesNo
17740045CODON OPTIMIZED REP1 GENES AND USES THEREOFMay 2022August 2022Allow310NoNo
17646496NOVEL PEPTIDE, COMPOSITIONS AND METHOD FOR DELIVERY OF AGENTS INTO CELLS AND TISSUESDecember 2021March 2023Allow1420NoNo
17616762ONCOLYTIC VIRUS FOR TREATING BRAIN TUMORS USING RECOMBINANT NEWCASTLE DISEASE VIRUS INTO WHICH NEWCASTLE DISEASE VIRUS VECTOR-BASED PTEN GENE IS INSERTED AND COMPOSITION FOR TREATING BRAIN TUMORS USING SAMEDecember 2021October 2022Allow1000NoNo
17507996Truncated Epiderimal Growth Factor Receptor (EGFRt) for Transduced T Cell SelectionOctober 2021May 2025Allow4310YesNo
17502101ENHANCED THERAPEUTIC USAGE OF A PURINE NUCLEOSIDE PHOSPHORYLASE OR NUCELOSIDE HYDROLASE PRODRUGOctober 2021April 2025Allow4210NoNo
17448549DOSING REGIME AND FORMULATIONS FOR TYPE B ADENOVIRUSESSeptember 2021February 2025Allow4110YesNo
17440372ADOPTIVE CELL THERAPYSeptember 2021December 2024Abandon3910NoNo
17463262CODON OPTIMIZED REP1 GENES AND USES THEREOFAugust 2021February 2022Allow500NoNo
17433222TUMOR-NAVIGATING, SELF-ERADICATING, TRAIL-ARMED SALMONELLA FOR PRECISION CANCER THERAPYAugust 2021August 2022Allow1210NoNo
17400974PRIMARY CELL GENE EDITINGAugust 2021May 2025Abandon4510NoNo
17387347Chimeric T Cell Receptors, Nucleic Acids, And Methods Of Making And Using The SameJuly 2021November 2024Allow4030NoNo
17339597TRANSPOSITION OF NUCLEIC ACID CONSTRUCTS INTO EUKARYOTIC GENOMES WITH A TRANSPOSASE FROM AMYELOISJune 2021March 2022Allow911NoNo
17327625THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMSMay 2021April 2024Abandon3540NoYes
17241546POLYEPITOPE CONSTRUCTS FOR USE IN IMMUNOTHERAPYApril 2021September 2024Abandon4020NoNo
17240845Optimized Liver-Specific Expression Systems for FVIII and FIXApril 2021October 2024Abandon4110NoNo
17287434SYNP151 (PROC29), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN RETINAL GANGLION CELLSApril 2021December 2024Abandon4410NoNo
17194009AAV VECTORS FOR RETINAL AND CNS GENE THERAPYMarch 2021October 2024Allow4410NoNo
17255091NATURAL KILLER CELLSDecember 2020May 2025Allow5211YesNo
17055056COMPOSITIOINS FOR INDUCING AN IMMUNE RESPONSENovember 2020November 2024Allow4811NoNo
17090110Dry Transfection Compositions and Methods for Making and Using the SameNovember 2020May 2025Allow5550NoNo
17079006BCMA CHIMERIC ANTIGEN RECEPTORSOctober 2020October 2023Allow3510NoNo
17079072BCMA CHIMERIC ANTIGEN RECEPTORSOctober 2020April 2021Allow610NoNo
17071707THERAPEUTIC METHODS AND COMPOSITIONS FOR SOLID DELIVERYOctober 2020January 2024Abandon3910NoNo
17067302LIPOSOME COMPOSITIONOctober 2020March 2021Allow610NoNo
16980345INDUCIBLE T CELL RECEPTORS AND USES THEREOFSeptember 2020February 2025Allow5310YesNo
17013195SELECTION METHODS FOR GENETICALLY-MODIFIED T CELLSSeptember 2020March 2024Abandon4210NoNo
17010587GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUSSeptember 2020March 2024Allow4361YesNo
16977015STEM CELL-DERIVED EXOSOMES FOR THE TREATMENT OF CORNEAL SCARRINGAugust 2020November 2024Allow5011NoNo
16976168LIPOSOMAL SPHERICAL NUCLEIC ACID (SNA) CONSTRUCTS FOR SURVIVAL OF MOTOR NEURON (SMA) INHIBITORSAugust 2020July 2024Abandon4710NoNo
16975545NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS HAVING REDUCED CAPSID DEAMIDATION AND USES THEREFORAugust 2020May 2025Allow5620YesYes
17000105Humanized M-CSF MiceAugust 2020June 2024Allow4620YesNo
16994388CANCER STEM CELL POPULATION AND METHOD FOR PRODUCTION THEREOFAugust 2020December 2023Allow4010NoNo
16992196THERAPEUTIC IMMUNE CELLS WITH IMPROVED FUNCTION AND METHODS FOR MAKING THE SAMEAugust 2020October 2023Abandon3810NoNo
16968664CRISPR/CAS9 VECTOR COMBINATION AND APPLICATION THEREOF IN GENE KNOCKOUTAugust 2020July 2021Allow1110YesNo
16986946METHODS AND COMPOSITIONS FOR TREATING METASTATIC BREAST CANCER AND OTHER CANCERS IN THE BRAINAugust 2020August 2023Allow3710YesNo
16966287METHODS FOR PREVENTING AND TREATING TYPE II DIABETESJuly 2020September 2024Allow5021YesNo
16933154METHODS FOR TREATING MUSCULAR DYSTROPHYJuly 2020July 2023Abandon3610NoNo
16963034GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYOTESJuly 2020March 2025Allow5621YesNo
16916482VESICULAR STOMATITIS VIRUSESJune 2020December 2022Allow2910NoNo
16903257MOTOR NEURON-SPECIFIC EXPRESSION VECTORSJune 2020January 2023Allow3110NoNo
16896021CAS9 NUCLEIC ACID MOLECULES AND THEIR USEJune 2020December 2022Allow3010NoNo
16893166PRIMARY CELL GENE EDITINGJune 2020August 2021Abandon1520YesNo
16891978METHODS AND COMPOSITIONS FOR THE TARGETED MODIFICATION OF A GENOMEJune 2020July 2023Allow3710NoNo
16885874TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPYMay 2020June 2021Allow1301YesNo
15733107Therapy For Myotonic Dystrophy Type 1 Via Genome Editing of the DMPK GeneMay 2020March 2025Abandon5841NoNo
16842709TRANSPOSITION OF NUCLEIC ACID CONSTRUCTS INTO EUKARYOTIC GENOMES WITH A TRANSPOSASE FROM AMYELOISApril 2020April 2021Allow1211NoNo
16837610BCMA CHIMERIC ANTIGEN RECEPTORSApril 2020December 2022Allow3210NoNo
16650987THREAD COLLECTING DEVICEMarch 2020June 2023Allow3810NoNo
16820101METHOD FOR IN VITRO FERTILIZATION IN A BIOREACTORMarch 2020August 2024Allow5330NoNo
16645707RNA REPLICON FOR REPROGRAMMING SOMATIC CELLSMarch 2020December 2024Allow5830YesNo
16807943GENETIC MARKERS FOR ENGRAFTMENT OF HUMAN CARDIAC VENTRICULAR PROGENITOR CELLSMarch 2020March 2023Allow3610NoNo
16799818Renovation and Repopulation of Decellularized Tissues and Cadaveric Organs by Stem CellsFebruary 2020July 2023Abandon4110NoNo
16784230ISOLATED LIVER CANCER STEM CELL AND METHOD FOR DRUG SCREENING THEREOFFebruary 2020June 2023Allow4020NoNo
16635857Treatment of Local Skin Hypotrophy ConditionsJanuary 2020June 2024Abandon5310NoNo
16742670TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USEJanuary 2020November 2020Allow1110NoNo
16724508COMPOSITIONS AND METHODS FOR THE STUDY AND TREATMENT OF ACUTE KIDNEY INJURYDecember 2019November 2023Abandon4620NoNo
16722071COMPOSITIONS AND METHODS FOR PEST CONTROL MANAGEMENTDecember 2019October 2022Allow3310NoNo
16714127TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORSDecember 2019November 2023Abandon4720NoNo
16696456Methods, Devices and Systems for Enhanced Transduction EfficiencyNovember 2019March 2024Allow5220YesNo
16613616REPROGRAMMING METABOLISM BY INHIBITING VHL FOR TREATMENT OF NEURODEGENERATIONNovember 2019November 2023Abandon4820NoNo
16662987ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSID AND METHODS OF USE THEREOFOctober 2019February 2023Abandon4010NoNo
16656497PIF-TRANSFECTED CELLS AND METHODS OF USEOctober 2019October 2023Abandon4810NoNo
16500706ADENO-ASSOCIATED VIRUS CAPSID VARIANTS AND METHODS OF USE THEREOFOctober 2019January 2023Allow3910YesNo
16584616RECOMBINANT AAV VARIANTS AND USES THEREOFSeptember 2019June 2022Allow3300NoNo
16578893METHODS, SYSTEMS, AND COMPOSITIONS FOR NEURONAL DIFFERENTIATION OF MULTIPOTENT STROMAL CELLSSeptember 2019December 2022Abandon3910NoNo
16577857NEUROPROTECTIVE MOLECULES AND METHODS OF TREATING NEUROLOGICAL DISORDERS AND INDUCING STRESS GRANULESSeptember 2019June 2024Abandon5720NoYes
16572248Using Truncated Guide RNAs (tru-gRNAs) to Increase Specificity for RNA-Guided Genome EditingSeptember 2019December 2022Allow3910YesNo
16489018SHP INHIBITOR COMPOSITIONS AND USES FOR CHIMERIC ANTIGEN RECEPTOR THERAPYAugust 2019January 2025Abandon6021NoYes
16541083METHODS FOR TRANSDUCTION AND CELL PROCESSINGAugust 2019June 2023Allow4611NoNo
16485094METHODS AND COMPOSITIONS FOR GENE TRANSFER ACROSS THE VASCULATUREAugust 2019October 2023Allow5020NoNo
16513999MARKERS FOR BREAST CANCERJuly 2019December 2022Abandon4110NoNo
16504853BCMA CHIMERIC ANTIGEN RECEPTORSJuly 2019January 2020Allow610NoNo
16504859BCMA CHIMERIC ANTIGEN RECEPTORSJuly 2019January 2020Allow610NoNo
16502972BCMA CHIMERIC ANTIGEN RECEPTORSJuly 2019December 2019Allow610NoNo
16502966BCMA CHIMERIC ANTIGEN RECEPTORSJuly 2019December 2019Allow610NoNo
16447812NUCLEIC ACID ENCODING GENETICALLY ENGINEERED GROWTH FACTOR VARIANTSJune 2019July 2024Abandon6040YesNo
16443841Population-Hastened Assembly Genetic EngineeringJune 2019January 2025Abandon6021NoYes
16434714TUMOR-TARGETING SYNTHETIC ADENOVIRUSES AND USES THEREOFJune 2019June 2023Allow4920NoNo
16465109ENGINEERED B CELLS AND RELATED COMPOSITIONS AND METHODSMay 2019June 2023Allow4811YesNo
16411848Novel Liver Targeting Adeno-Associated Viral VectorsMay 2019June 2023Allow4920YesNo
16395865Tolerogenic DNA VaccineApril 2019July 2021Allow2631NoNo
16384571GENE VECTORApril 2019March 2022Allow3500NoNo
16340758USE OF TONICIFYING AGENTS TO ENHANCE RECOMBINANT ADENO-ASSOCIATED VIRUS YIELDApril 2019June 2023Allow5020NoNo
16366826NON-HUMAN ANIMALS HAVING A DISRUPTION IN A C9ORF72 LOCUSMarch 2019August 2022Allow4110YesNo
16296925NOVEL PLGA-MODIFIED POLYETHYLENIMINE SELF-ASSEMBLY NANOTECHNOLOGY FOR NUCLEIC ACID AND DRUG DELIVERYMarch 2019August 2022Allow4210NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ARON, KIMBERLY A.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
6
Examiner Affirmed
4
(66.7%)
Examiner Reversed
2
(33.3%)
Reversal Percentile
48.3%
Lower than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
50
Allowed After Appeal Filing
3
(6.0%)
Not Allowed After Appeal Filing
47
(94.0%)
Filing Benefit Percentile
9.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 6.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ARON, KIMBERLY A - Prosecution Strategy Guide

Executive Summary

Examiner ARON, KIMBERLY A works in Art Unit 1633 and has examined 410 patent applications in our dataset. With an allowance rate of 52.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.

Allowance Patterns

Examiner ARON, KIMBERLY A's allowance rate of 52.7% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ARON, KIMBERLY A receive 2.45 office actions before reaching final disposition. This places the examiner in the 84% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ARON, KIMBERLY A is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +35.1% benefit to allowance rate for applications examined by ARON, KIMBERLY A. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 19.6% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 21.2% of cases where such amendments are filed. This entry rate is in the 19% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 80.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 60% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 77.8% of appeals filed. This is in the 65% percentile among all examiners. Of these withdrawals, 90.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 73.1% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.5% of allowed cases (in the 59% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.9% of allowed cases (in the 55% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.